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Abstract: New compounds are needed to treat acne and superficial infections caused by 
Propionibacterium acnes and Staphylococcus aureus due to the reduced effectiveness of 
agents used at present. Long-chain polyunsaturated fatty acids (LC-PUFAs) are attracting 
attention as potential new topical treatments for Gram-positive infections due to their 
antimicrobial potency and anti-inflammatory properties. This present study aimed to 
investigate the antimicrobial effects of six LC-PUFAs against P. acnes and S. aureus to 
evaluate their potential to treat infections caused by these pathogens. Minimum inhibitory 
concentrations were determined against P. acnes and S. aureus, and the LC-PUFAs were 
found to inhibit bacterial growth at 32–1024 mg/L. Generally, P. acnes was more 
susceptible to the growth inhibitory actions of LC-PUFAs, but these compounds were 
bactericidal only for S. aureus. This is the first report of antibacterial activity attributed to 
15-hydroxyeicosapentaenoic acid (15-OHEPA) and 15-hydroxyeicosatrienoic acid 
(HETrE), while the anti-P. acnes effects of the six LC-PUFAs used herein are novel 
observations. During exposure to the LC-PUFAs, S. aureus cells were killed within  
15–30 min. Checkerboard assays demonstrated that the LC-PUFAs did not antagonise the 
antimicrobial potency of clinical agents used presently against P. acnes and S. aureus. 
However, importantly, synergistic interactions against S. aureus were detected for 
combinations of benzoyl peroxide with 15-OHEPA, dihomo-γ-linolenic acid (DGLA) and 
HETrE; and neomycin with 15-OHEPA, DGLA, eicosapentaenoic acid, γ-linolenic acid 
and HETrE. In conclusion, LC-PUFAs warrant further evaluation as possible new agents to 
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treat skin infections caused by P. acnes and S. aureus, especially in synergistic 
combinations with antimicrobial agents already used clinically. 
Keywords: acne vulgaris; benzoyl peroxide; C20:5n-3; combination therapy; 
docosahexaenoic acid (DHA); natural products; omega-3; skin infection; synergy 
 
1. Introduction 
Colonisation of the skin by the anaerobic Gram-positive bacterium Propionibacterium acnes is one 
factor involved in the aetiology of acne vulgaris [1,2]. In addition, colonisation by Staphylococcus 
aureus, an opportunistic Gram-positive pathogen, has been implicated in the pathogenesis of acne [1], 
and this bacterium can also cause superficial skin infections such as boils, pimples and impetigo [3]. 
Topical treatment and management of acne relies on the application of benzoyl peroxide (BPO), 
salicylic acid (SA) and certain antibiotics, while topical S. aureus infections are typically treated with 
fusidic acid (FUS), mupirocin (MUP), neomycin (NEO) and polymyxin B (POL) [4]. However, there 
has been a decrease in the clinical efficacy of many treatment agents during the last 20 years, perhaps 
due to the increasing prevalence of drug-resistant P. acnes and S. aureus strains [5–8]. Moreover, some 
of these agents are associated with undesirable side effects such as skin irritation [4], meaning that 
there is a clinical need to identify alternative compounds with improved therapeutic properties for 
topical infections caused by P. acnes and S. aureus. 
Fatty acids are attracting attention as potential therapeutic antimicrobial agents due to their potency, 
broad spectrum of activity and the lack of classical resistance mechanisms against the actions of these 
compounds [9,10]. In particular, various long-chain polyunsaturated fatty acids (LC-PUFAs), which 
are found naturally at high levels in many marine organisms [11], have been shown to exert highly 
potent activity against Gram-positive bacteria, including eicosapentaenoic acid (EPA;  
C20:5n-3) [12,13], docosahexaenoic acid (DHA; C22:6n-3) [14–17], γ-linolenic acid (GLA;  
C18:3n-6) [15,18–21] and dihomo-γ-linolenic acid (DGLA; C20:3n-6) [15]. Furthermore, LC-PUFAs 
deserve special consideration for topical application because they are often associated with  
anti-inflammatory properties, which may provide supplementary benefit during therapy [10,22,23]. 
Thus, the aim of this present study was to investigate the antimicrobial effects of six LC-PUFAs 
(DGLA, DHA, EPA, GLA, 15-hydroxyeicosatrienoic acid [HETrE], and 15-hydroxyeicosapentaenoic 
acid [15-OHEPA]) against P. acnes and S. aureus, to evaluate the potential of these compounds for 
treating topical infections caused by these pathogens. 
2. Results 
2.1. Antibacterial Activity of Six LC-PUFAs against P. acnes and S. aureus 
Minimum inhibitory (MIC) and bactericidal (MBC) concentrations for six LC-PUFAs (DHA, EPA, 
GLA, DGLA, HETrE and 15-OHEPA) were determined by broth micro-dilution against P. acnes 
NCTC737 and S. aureus ATCC43300. In all tests, ethanol and dimethyl sulfoxide (DMSO) carrier 
solvents had no detectable effect on the growth of these test bacteria. HETrE and DHA were the most 
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effective LC-PUFAs for inhibiting the growth of P. acnes (MIC = 32 mg/L) followed by GLA  
(MIC = 64 mg/L) (Table 1). None of the LC-PUFAs killed P. acnes up to the maximum concentration 
tested (4096 mg/L). Meanwhile, DHA and EPA were the most effective LC-PUFAs against S. aureus 
(MICs = 128 mg/L), but the LC-PUFAs were generally less effective against this bacterium. Indeed, 
the MIC for each LC-PUFA was up to eight-fold greater against S. aureus compared with P. acnes 
(Table 1); however, in contrast to observations for P. acnes, each of the six LC-PUFAs was 
bactericidal against S. aureus and MBC values were equal to MIC or 2 × MIC (Table 1). Next, to 
assess interstrain variability in susceptibility to the LC-PUFAs, MIC50 and MBC50 values were 
determined using ten isolates of S. aureus from diverse backgrounds, including clinical and laboratory 
strains and isolates with resistance to methicillin and vancomycin (Table 2). MIC50 and MBC50 values 
correspond to the concentrations required to inhibit or kill 50% of the strains tested, respectively. The 
relative potency of the LC-PUFAs against these S. aureus isolates was: DHA > EPA > GLA > HETrE 
> 15-OHEPA = DGLA (Table 2). 
Table 1. MICs and MBCs against P. acnes NCTC737 and S. aureus ATCC43300 for  
six LC-PUFAs. 
Compound P. acnes  S. aureus 
MIC (mg/L) MBC (mg/L)  MIC (mg/L) MBC (mg/L) 
DGLA 128 >4096  1024 1024 
DHA 32 >4096  128 128 
EPA 128 >4096  128 256 
GLA 64 >4096  512 512 
HETrE 32 >4096  256 512 
15-OHEPA 128 >4096  512 1024 
Table 2. MIC50 and MBC50 values for six LC-PUFAs against ten diverse isolates of  
S. aureus. 
Compound S. aureus 
MIC50 (mg/L) MBC50 (mg/L) 
DGLA 1024 2048 
DHA 128 256 
EPA 256 256 
GLA 512 512 
HETrE 512 1024 
15-OHEPA 1024 2048 
2.2. Killing Kinetics of Six LC-PUFAs against S. aureus 
The killing kinetics of the six LC-PUFAs were determined at 1 × MBC against ~2.6 × 10
5
 colony 
forming unit (CFU)/mL inoculums of S. aureus ATCC43300 prepared in phosphate-buffered saline 
(PBS). The incubations were performed at 37 °C and there was little change in the viability of cells in 
the control group that were exposed only to the carrier solvents, ethanol and DMSO. Importantly, the 
LC-PUFAs killed the S. aureus inoculums rapidly and no viable bacteria were detected within 15 min 
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of initial exposure for five of the six LC-PUFAs, with DGLA taking just 30 min to completely kill the 
inoculum (Figure 1). 
Figure 1. Killing kinetics of six LC-PUFAs against a S. aureus ATCC43300 inoculum of 
~2.6 × 10
5
 colony forming unit (CFU)/mL in phosphate-buffered saline (PBS) showing 
that each LC-PUFA killed the bacteria rapidly. n = 3; mean ± one standard deviation (not 
all error bars are visible). Please note that a single kill curve is shown for DHA, EPA, 
HETrE and 15-OHEPA because the values were identical and the kill curves  
overlapped exactly. 
 
2.3. Efficacy of Six LC-PUFAs in Combination with Clinical Antimicrobial Agents 
Combination therapies are often prescribed during the treatment of acne vulgaris and topical 
staphylococcal infections [1,2,4] because this approach can improve clinical outcome and may also 
reduce the opportunity to select for drug-resistant strains [24]. Therefore, to assess whether the  
LC-PUFAs could be used without reducing the efficacy of agents currently prescribed to treat acne and 
topical staphylococcal infections, checkerboard tests were performed for each LC-PUFA in 
combination with six topical antimicrobials. Moreover, these tests enabled us to evaluate whether any 
of the combinations acted in synergy, as synergistic combinations of antimicrobial agents can deliver 
enhanced efficacy through greater potency and also reduce undesirable side effects due to the 
application of lower doses of individual agents [24]. Initially, MICs and MBCs had to be determined 
against P. acnes and S. aureus for two antimicrobial agents used to treat acne vulgaris (BPO and SA) 
and additionally against S. aureus for four antibiotics used clinically in the treatment of topical 
staphylococcal infections (FUS, MUP, NEO and POL) (Table 3). The MIC against P. acnes for BPO 
and SA was 64 mg/L but these agents failed to kill the bacterium up to 4096 mg/L, which was the 
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maximum concentration tested (Table 3). Against S. aureus, the MIC and MBC for BPO was  
512 mg/L, while the MIC and MBC for SA was 512 mg/L and 1024 mg/L, respectively, meaning that 
these agents were less potent against S. aureus compared with P. acnes. FUS and MUP were the most 
potent clinical agents against S. aureus (MICs = 0.25 mg/L), while POL and NEO were less effective 
(Table 3). Nevertheless, all six clinical antimicrobials exhibited bactericidal activity against S. aureus 
at minimum concentrations up to 64 × MIC (Table 3). 
Table 3. MICs and MBCs against P. acnes NCTC737 and S. aureus ATCC43300 for 
various clinical antimicrobial agents used to treat acne or superficial topical staphylococcal 
infections. n/d, not determined. 
Compound P. acnes  S. aureus 
MIC (mg/L) MBC (mg/L)  MIC (mg/L) MBC (mg/L) 
BPO 64 >4096  512 512 
FUS n/d n/d  0.25 8 
MUP n/d n/d  0.25 16 
NEO n/d n/d  32 128 
POL n/d n/d  16 128 
SA 64 >4096  1024 2048 
Using the pre-determined MIC values, checkerboard assays were performed to detect the 
interactions between the LC-PUFAs and the clinical antimicrobial drugs against the growth of P. acnes 
and S. aureus. The fractional inhibitory concentration (FIC) on duplicate checkerboards was used to 
calculate a mean FIC for each interaction, and mean FIC ≤ 0.5 was defined as synergy while mean  
FIC ≥ 4 was defined as antagonism [25]. None of the combinations tested against P. acnes gave mean 
FICs of ≤0.5 or ≥4, indicating no growth inhibitory synergy or antagonism, respectively (Table 4). 
Against S. aureus, none of the combinations gave a mean FIC ≥ 4, indicating no antagonism of 
efficacy between the LC-PUFAs and the clinical antimicrobial agents (Table 5). Interestingly, several 
combinations of LC-PUFAs and clinical agents showed antimicrobial synergy against S. aureus, 
including BPO with 15-OHEPA, DGLA and HETrE; and, most notably, NEO with five of the six  
LC-PUFAs, with the exception being DHA that had an FIC of 0.56 meaning that it only just failed to 
meet the definition of synergy (Table 5). 
Table 4. Mean FIC values of interactions between six LC-PUFAs and two topical 
antimicrobial agents against P. acnes NCTC737 showing that none of the combinations 
were synergistic or antagonistic. n = 2; mean ± one standard deviation. 
P. acnes DGLA DHA EPA GLA HETrE 15-OHEPA 
BPO 1.50 ± 0.71 1.50 ± 0.71 1.50 ± 0.71 1.50 ± 0.71 0.75 ± 0.00 0.88 ± 0.18 
SA 2.00 ± 0.00 1.13 ± 0.53 0.78 ± 0.31 1.50 ± 0.71 1.75 ± 0.35 2.00 ± 0.00 
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Table 5. Mean FIC values of interactions between six LC-PUFAs and six topical 
antimicrobial agents against S. aureus ATCC43300 showing that there was synergy  
(FIC ≤ 0.5) between BPO with three LC-PUFAs and NEO with five LC-PUFAs. Values in 
bold indicate synergy; n = 2; mean ± one standard deviation. 
S. aureus DGLA DHA EPA GLA HETrE 15-OHEPA 
BPO 0.44 ± 0.09 2.00 ± 0.00 1.00 ± 0.00 0.56 ± 0.09 0.50 ± 0.00 0.44 ± 0.09 
SA 2.00 ± 0.00 1.25 ± 0.35 0.88 ± 0.18 0.88 ± 0.18 0.88 ± 0.18 1.00 ± 0.00 
FUS 0.81 ± 0.27 2.00 ± 0.00 1.13 ± 0.18 1.50 ± 0.71 1.50 ± 0.71 2.00 ± 0.00 
MUP 1.50 ± 0.71 1.50 ± 0.00 2.00 ± 0.00 2.25 ± 0.35 2.00 ± 0.00 1.38 ± 0.88 
NEO 0.28 ± 0.13 0.56 ± 0.09 0.38 ± 0.00 0.19 ± 0.00 0.38 ± 0.00 0.34 ± 0.04 
POL 1.78 ± 1.72 2.00 ± 0.00 2.00 ± 0.00 1.06 ± 0.62 0.75 ± 0.00 0.94 ± 0.27 
3. Discussion 
New treatments are required for topical infections caused by P. acnes and S. aureus as the efficacy 
of many treatments has reduced due to drug resistance and undesirable side effects can also cause 
problems for patients. In this present study, the antimicrobial effects of six LC-PUFAs were 
investigated and each compound potently inhibited the growth of P. acnes and S. aureus in vitro. 
Moreover, each LC-PUFA was bactericidal against S. aureus and caused cell death within just 30 min. 
Notably, none of the LC-PUFAs antagonised the antimicrobial activity of agents used to treat topical 
infections caused by these two pathogens; however, various combinations of LC-PUFAs with BPO or 
NEO acted synergistically to inhibit the growth of S. aureus. 
Though LC-PUFAs are known to be potently antibacterial [9], to our knowledge this is the first 
time that 15-OHEPA and HETrE have been shown to exert antimicrobial activities. Furthermore, this 
is the first study to report that the six LC-PUFAs tested herein are detrimental for the growth of  
P. acnes, though other fatty acids are known to be toxic to this bacterium, including α-linolenic acid 
(C18:3n-3) [26] and lauric acid (C12:0) [27]. Despite LC-PUFAs lacking bactericidal action against  
P. acnes, these compounds did exert similar antibacterial potency as BPO and SA indicating that 
potency should not prevent LC-PUFAs being considered as alternative agents in acne therapy. The 
antimicrobial potency of BPO against P. acnes in this present study is similar to previous reports, but 
the lack of bactericidal activity, such as has been reported previously, may stem from methodological 
differences in quantifying antimicrobial action and the preparation of the inoculum, as well as the use 
of different growth conditions and bacterial strains [27–29]. Despite no indication of P. acnes 
resistance to LC-PUFAs, the probability to select for strains with resistance to the action of these 
compounds warrants investigation, particularly as a large difference was observed between MIC and 
MBC values that may increase the opportunity for mutant selection [30]. 
Confirming previous observations, EPA, DHA and GLA were potently antibacterial against  
S. aureus [18,21,31], but the activity of DGLA against this pathogen is reported here for the first time. 
Knapp and Melly [32] did show that a C20:3 fatty acid had anti-S. aureus activity, but it was not clear 
which specific fatty acid isomer was used. The LC-PUFAs were similarly potent against a variety of  
S. aureus strains, suggesting that interstrain susceptibility should not present difficulties during future 
clinical use. The bactericidal action and small differences between MIC and MBC values against  
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S. aureus should reduce the chances to select for resistant strains, but this requires experimental 
confirmation [30]. 
The LC-PUFAs killed S. aureus rapidly with kill times similar to earlier observations for other fatty 
acids against this bacterium, including caprylic acid (C8:0) [33], lauric acid [34], sapienic acid 
(C16:1n-10) [35,36], oleic acid (C18:1n-9) [37], GLA [19] and EPA [38]. Such rapid cell death caused 
by the LC-PUFAs strongly suggests a cell membrane lytic mechanism of action against S. aureus, 
which is in line with previous studies on Gram-positive species (see review by Desbois and Smith [9]). 
However, the lack of bactericidal action against P. acnes even at high concentrations (4096 mg/L) 
suggests a different mode of action for LC-PUFAs against this bacterium and growth inhibition could 
result from disruption at multiple cellular targets [9]. The underlying antimicrobial mechanisms of  
LC-PUFAs against P. acnes merit further investigation. 
In checkerboard tests, none of the LC-PUFAs antagonised the efficacy of the topical antimicrobial 
treatments used against P. acnes and S. aureus, suggesting that the LC-PUFAs could be added to 
current treatment regimens without reducing clinical effectiveness. The checkerboards revealed no 
antimicrobial synergy against P. acnes between LC-PUFAs with BPO and SA, even though an earlier 
study showed that the efficacy of BPO was enhanced in presence of lipid compounds [28]. Against  
S. aureus, three of the six LC-PUFAs acted in synergy with the anti-acne agent BPO, while five of the 
LC-PUFAs acted synergistically with the aminoglycoside antibiotic NEO. One major benefit of such 
antimicrobial combinations is the reduced opportunity to select for resistant bacterial strains [24]. Few 
studies have examined the interactions of fatty acids and LC-PUFAs with clinical antibiotics against 
bacteria [36,39,40], but the findings in this present study emphasise the potential importance of testing 
for such synergism as has been highlighted elsewhere [9,13]. At this stage, the nature of the synergy 
between the LC-PUFAs with BPO or NEO is unknown but one may speculate that they improve the 
penetration of the clinical agents into the cell because fatty acids can increase cell membrane 
permeability [41]. The synergy between BPO and certain LC-PUFAs could be exploited to reduce the 
concentrations of compounds applied to the skin during acne therapy and this could reduce the severity 
of undesirable side effects. The discovery of synergy between LC-PUFAs and NEO may have 
uncovered an important new strategy to combat S. aureus infections. Synergy has been reported 
between aminoglycoside antibiotics and a fatty acid-rich oil but few details of the oil composition were 
given and it was unclear which components were actively involved [42]. 
Of course, this present study is limited to in vitro observations and in vivo studies are needed to 
understand the true potential of applying LC-PUFAs in combination with clinical antimicrobial drugs 
for treating P. acnes and S. aureus infections. The prospects for using LC-PUFAs to treat P. acnes and 
S. aureus infections appear to be promising because other fatty acids have shown topical efficacy  
in vivo against these pathogens, including lauric acid against P. acnes in a murine ear skin infection 
model [27]; sapienic acid against S. aureus in a murine dermatitis model [36]; and oleic acid  
(C18:1n-9) against topical staphylococcal infections in mice [43,44]. Furthermore, 10-undecylenic acid 
(C11:1n-1) is used already as a topical agent for the treatment of fungal infections [45]. Fatty acids are 
antimicrobial components of the innate immune system found on mammalian skin and the application 
of exogenous LC-PUFAs during therapy would augment these natural defences [46–50]. Further 
benefit may be realised because fatty acids can synergise with natural antimicrobial peptides found on 
human skin [51]. Moreover, reductions in the prescription of conventional antibiotics for topical 
Mar. Drugs 2013, 11 4551 
 
 
infections, especially systemic agents, will beneficially reduce the opportunity to select for  
drug-resistant strains in the non-target skin microbiota [1,7]. 
4. Experimental Section 
4.1. Reagents and Bacteria 
All bacterial culture media and reagents were of the highest purity available and purchased from 
Sigma-Aldrich Ltd. (Poole, UK) unless stated. The molecular structures of the fatty acids used in this 
present study are shown in Figure 2. Stock solutions of DGLA (97.9%; Equateq Ltd., Callanish, UK), 
HETrE (94.3%; Equateq Ltd., Callanish, UK), 15-OHEPA (50 mg/mL; Sapala Organics Pvt. Ltd., 
Hyderabad, India) and BPO (75%) were prepared in DMSO (≥99.9%) to 50 mg/mL; DHA, EPA and 
GLA were prepared in ethanol to 100 mg/mL; POL and FUS were prepared in sterile distilled water to 
20 mg/mL; while MUP and SA were prepared in ethanol to 50 mg/mL. NEO was purchased as a 10 
mg/mL solution in sterile saline. P. acnes NCTC737 was purchased from the National Collection of 
Type Cultures (Porton Down, UK). Ten strains of S. aureus were used: two community-acquired 
meticillin-resistant (MRSA) clinical isolates (CA3 and NRS384), one hospital-acquired MRSA clinical 
isolate (HA204), two vancomycin-intermediate resistant clinical isolates (5827 and 5836), the 
reference MRSA strain ATCC43300 (gifted by Dr. Peter Warn, University of Manchester, Manchester, 
UK), the “laboratory” MRSA strain BB270 and three “laboratory” meticillin-susceptible strains 
(Newman, SH1000 and RN4220). S. aureus strains were sourced as described in Desbois et al. [52]. 
Figure 2. Molecular structures of the six LC-PUFAs used in this present study. All double 
bonds are in cis orientation except for the n-7 bonds of 15-HETrE and 15-OHEPA that are 
in trans orientation. 
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4.2. MIC and MBC Determinations 
MICs and MBCs were determined for the six LC-PUFA and various clinical antimicrobial agents 
against P. acnes and S. aureus by broth micro-dilution according to protocols M07-A8 and M11-A5 
published by the Clinical and Laboratory Standards Institute [53,54]. Doubling dilutions of the test 
compounds were prepared in sterile 96-well plates up to 4096 mg/L. S. aureus experiments were 
performed in Mueller-Hinton broth (MHB), while P. acnes studies used supplemented brucella broth 
(SBB) [54]. Inoculums of S. aureus were prepared from late logarithmic phase cultures (~18 h) that 
had been grown in 5 mL MHB at 37 °C with agitation at 140 rpm, while the P. acnes inoculum was 
prepared in 2–3 mL SBB by re-suspending colonies from supplemented brucella agar (SBA) plates 
that had been grown anaerobically (10% CO2, 10% H2, 80% N2) for ~72 h at 37 °C (A85 Workstation; 
Don Whitley Scientific Ltd., Shipley, UK). Absorbance readings at 540 nm and 570 nm of the P. acnes 
and S. aureus suspensions were determined respectively, and bacterial inoculums were adjusted to  
1 × 10
7
 CFU/mL with fresh medium. Inoculum sizes were confirmed by diluting in phosphate-buffered 
saline (PBS) and plating on Mueller-Hinton agar (MHA) or SBA. Each well was inoculated with 5 µL 
of bacterial suspension. Control wells contained media inoculated with bacterial suspension only, 
while negative control wells contained uninoculated culture medium only. Further inoculated wells 
controlled for the antimicrobial effects of the greatest concentrations of ethanol and DMSO used in the 
test wells (4.5% and 9.6%, respectively). Microtitre plates were incubated at 37 °C for 18–20 h (48 h 
for P. acnes), and then the MICs were determined to be the lowest concentrations of each compound 
that prevented visible bacterial growth. MBCs were determined by plating 50 µL from each well 
showing no visible growth on to MHA or SBA and incubating these plates at 37 °C for 48 h (96 h for 
P. acnes). The MBCs were the lowest concentrations of each compound that killed ≥99.9% of the 
initial inoculum. MIC and MBC determinations were performed in duplicate. MIC50 and MBC50 values 
were obtained by performing MICs and MBCs against the ten S. aureus isolates described above, and 
then determining the concentration required to inhibit or kill 50% of the strains, respectively. 
4.3. Kill Kinetics 
A S. aureus ATCC43300 inoculum was prepared as above, except that PBS was used to adjust the 
suspension to 1 × 10
7
 CFU/mL. The inoculum was diluted and plated on MHA to provide an accurate 
indication of CFU/mL. Solutions in PBS of the six LC-PUFAs were prepared at 1 × MBC and 300 µL 
of each solution was dispensed to separate Eppendorf tubes. Controls contained just ethanol and 
DMSO diluted in PBS to the greatest concentration of each solvent used (0.5% and 2.1%, 
respectively). Each tube was inoculated with bacterial suspension (15 µL) and incubated statically at 
37 °C. At 15 min, 30 min, 1 h and 2 h, 10 µL from each tube was plated on MHA in duplicate. Plates 
were incubated at 37 °C for 24 h and then CFU were quantified. The experiment was performed  
in triplicate. 
4.4. Checkerboard Tests  
Checkerboard assays were performed according to the standard protocol published by the American 
Society for Microbiology [55] to investigate the antimicrobial interactions between the six LC-PUFAs 
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and two anti-acne agents (BPO and SA) against P. acnes. Further checkerboards were performed 
against S. aureus for BPO, SA, FUS, MUP, NEO and POL with these agents being assessed separately 
against each of the six LC-PUFAs. Doubling dilutions of each compound were prepared in MHB or 
SBB and dispensed to 96-well plates in the standard checkerboard pattern. Concentrations of each 
compound ranged from ≤1/16 × MIC to ≥4 × MIC. Control wells were dispensed with medium 
supplemented with the greatest concentration of solvent used in any well (4.5% ethanol and/or  
4.5% DMSO), while negative control wells contained just medium. Inoculums were prepared to  
1 × 10
7
 CFU/mL as above. Each well (except for negative controls) was inoculated with 5 µL of 
bacterial suspension. Plates were incubated as for MIC determinations above and then the presence of 
bacterial growth was determined for each well according to the clarity of the medium and/or the 
presence of suspended colonies. The FIC for each well was determined for each interaction and the 
FICs from duplicate checkerboard assays were used to calculate a mean value that permitted 
interpretation of the nature of interaction between each combination of compounds. 
5. Conclusions 
There is a need for alternative agents to treat acne and superficial skin infections caused by P. acnes 
and S. aureus due to drug-resistance and undesirable side effects associated with certain clinical agents 
used at present. LC-PUFAs have attracted attention as new agents against these pathogens due to their 
potent antimicrobial actions and potential anti-inflammatory properties. This present study 
demonstrates that these natural compounds deserve further evaluation for the treatment of infections 
caused by P. acnes and S. aureus, and LC-PUFAs could be applied in combination with some 
currently available treatments to enhance therapeutic efficacy. 
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